Combidex faces panel review
This article was originally published in The Gray Sheet
Executive Summary
Advanced Magnetics' iron oxide nanoparticle-based MRI contrast agent will be evaluated by CDER's Oncologic Drug Advisory Committee March 3. The panel presentation will be jointly prepared by Advanced Magnetics and Cytogen, which holds exclusive U.S. licensing and marketing rights to the product. Combidex's user fee goal date is March 30...